Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too? - Test2 - elhamkhani - TriplyDB

Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?

Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?

http://www.wikidata.org/entity/Q37114367

about

Addressing current challenges in cancer immunotherapy with mathematical and computational modelling.Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.A Single-Chain-Based Hexavalent CD27 Agonist Enhances T Cell Activation and Induces Anti-Tumor Immunity

P2860

Q33861540-96311CAE-EE8C-48C7-A9A9-8E73BAE16857 Q47325431-8B8DE4E4-BCEC-481A-BBF0-F5195E5DD9EB Q57300170-DB0442CF-5679-4AD1-9090-5CE38211EFA2

P2860

Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?

http://www.wikidata.org/entity/Q37114367

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 08 February 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Enhancing the safety of antibo ...... have our cake and eat it too?

@en

Enhancing the safety of antibo ...... have our cake and eat it too?

@nl

type

label

Enhancing the safety of antibo ...... have our cake and eat it too?

@en

Enhancing the safety of antibo ...... have our cake and eat it too?

@nl

prefLabel

Enhancing the safety of antibo ...... have our cake and eat it too?

@en

Enhancing the safety of antibo ...... have our cake and eat it too?

@nl

P1433

Q37114367-05CCD485-ECC0-4C32-A8C3-28319BB204E4

P1476

Q37114367-F11746F0-38C9-4032-A66B-BF031EB5DC3F

P2093

Q37114367-03C1FDB2-E3F6-4277-83FE-6FE81FC2A111

Q37114367-40DFE56A-5FD3-4C74-A7A3-ECC61F1E271D

Q37114367-88B1B04C-94E3-45A9-BDD5-25BBAF259057

Q37114367-8F3B0E00-5916-4098-A595-8BA272C0FFB9

P2860

Q37114367-00BF89F1-74BF-4676-B719-03804670E53E

Q37114367-04206146-37BF-4A26-8A85-36B73CF2E734

Q37114367-04498B9B-A626-454E-AB55-562861308BF8

Q37114367-0481F39E-E4FA-4252-B3A9-1F7F42A758E2

Q37114367-0AA9AB8E-A6D7-4FFC-8FB0-344A8C1D2118

Q37114367-0AC847A3-79CE-4AF7-B174-A041E5CD51D4

Q37114367-0AE914BE-F9C4-4CA4-99E9-378AC3869011

Q37114367-0AF2D974-FAF1-4D45-9222-4042CFF0CD2F

Q37114367-0B83E78F-F1E8-4766-B566-BBDD28B0E001

Q37114367-0BBBF592-5A8B-4589-A67F-DC5D7F85E8E2

P304

Q37114367-81E66452-7273-4936-BD8C-6F32E5BC52BF

P31

Q37114367-4A289216-050B-4906-8EE9-C914C1ED5AC4

P356

Q37114367-D0467C99-210F-4C2B-BE49-8108B7F3CC6C

P407

Q37114367-D1569212-AAA3-44F4-88DE-8172211EFE28

P433

Q37114367-D4D0FAA6-F997-459B-9998-4DCC72E64140

P478

Q37114367-EA5481EE-BFA2-4882-8859-13D87E7940E7

P577

Q37114367-0AAA2D31-2E18-4A5D-878D-7DF5496B9BD6

P698

Q37114367-44E755FD-74D5-442E-B904-FFBA1C790759

P921

Q37114367-FE98A1CF-60AC-4014-A38C-89AE50F2BA3E

P932

Q37114367-2176BEDB-B988-4F7A-BCAC-D20A75ED6DEA

P356

14712598.2016.1152256

P1433

Expert Opinion on Biological Therapy

P1476

Enhancing the safety of antibo ...... have our cake and eat it too?

@en

P2093

Adam J Adler

http://www.w3.org/2001/XMLSchema#string

Anthony T Vella

http://www.w3.org/2001/XMLSchema#string

Jeffrey S Wasser

http://www.w3.org/2001/XMLSchema#string

Joseph M Ryan

http://www.w3.org/2001/XMLSchema#string

P2860

Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.

Improved endpoints for cancer immunotherapy trials

Rituximab: mechanism of action

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

Massive genomic rearrangement acquired in a single catastrophic event during cancer development

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation

P304

655-674

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14712598.2016.1152256

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2016-02-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26855028

http://www.w3.org/2001/XMLSchema#string

P921

P932

4955764

http://www.w3.org/2001/XMLSchema#string